Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety Study in Adolescent and Adult Patients With Asthma

ClinicalTrials.gov ID: NCT01476904

Public ClinicalTrials.gov record NCT01476904. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 3-month Safety Evaluation Extension to the 12-week E004-C Study in Asthma Patients (A Double Blinded, Placebo-controlled, Parallel, 3-month Safety Study in Adolescent and Adult Patients With Asthma)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in a double-blinded manner.

Study identification

NCT ID
NCT01476904
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Enrollment
208 participants

Conditions and interventions

Conditions

Eligibility (public fields only)

Age range
12 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2011
Primary completion
Mar 31, 2012
Completion
Jun 30, 2012
Last update posted
Feb 12, 2017

2011 – 2012

United States locations

U.S. sites
27
U.S. states
16
U.S. cities
27
Facility City State ZIP Site status
Amphastar Site 0006 Costa Mesa California 92626
Amphastar Site 0005 Los Angeles California 90048
Amphastar Site 0004 Orange California 92868
Amphastar Site 0001 San Jose California 95117
Amphastar Site 0003 Stockton California 95207
Amphastar Site 0008 Denver Colorado 80230
Amphastar Site 0009 Wheat Ridge Colorado 80033
Amphastar Site 0011 Iowa City Iowa 52240
Amphastar Site 0013 North Dartmouth Massachusetts 02747
Amphastar Site 0014 Minneapolis Minnesota 55402
Amphastar Site 0015 Plymouth Minnesota 55441
Amphastar Site 0016 St Louis Missouri 63141
Amphastar Site 0017 Bozeman Montana 59718
Amphastar Site 0019 Bellevue Nebraska 68123
Amphastar Site 0020 Skillman New Jersey 08558
Amphastar Site 0018 Raleigh North Carolina 27607
Amphastar Site 0021 Cincinnati Ohio 45242
Amphastar Site 0024 Ashland Oregon 97520
Amphastar Site 0022 Eugene Oregon 97401
Amphastar Site 0023 Lake Oswego Oregon 97035
Amphastar Site 0025 Medford Oregon 97504
Amphastar Site 0026 Portland Oregon 97202
Amphastar Site 0029 North Charleston South Carolina 29406
Amphastar Site 0031 El Paso Texas 79903
Amphastar Site 0030 New Braunfels Texas 78130
Amphastar Site 0033 Richmond Virginia 23229
Amphastar Site 0034 Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01476904, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 12, 2017 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01476904 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →